SEC Form 4 · accession 0001213900-15-000657
Icagen, Inc. · ICGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clive Kabatznik
Director
Period of report
Jan 31, 2015
Accepted (ET)
Feb 3, 2015 · 3:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001518520
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF1 | $3.00 | Jan 31, 2015 | J | 30,000 | D | Apr 30, 2013 | Apr 30, 2015 | Common Stock | 30,000 | 0 | D |
| WarrantF1 | $2.10 | Jan 31, 2015 | J | 30,000 | A | Jan 31, 2015 | Mar 25, 2018 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1On January 31, 2015, Mr. Kabatznik exchanged 30,000 existing warrants that had an exercise price of $3.00 per share that he acquired in the Company's 2013 bridge financing private placement for 30,000 replacement warrants that have an exercise price of $2.10 per share. The replacement warrants do not contain anti-dilution price protection for issuances of securities at per share prices that are lower than the exercise price, are assignable by their holders and provide for certain buy-in-rights in the event that the Company fails to deliver shares of common stock underlying the warrant in a timely manner.